Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPRAZOLAM vs CHLORDIAZACHEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Generalized anxiety disorder,Panic disorder with or without agoraphobia,Anxiety (off-label),Insomnia (off-label),Chemotherapy-induced nausea and vomiting (off-label),Premenstrual dysphoric disorder (off-label)
Anxiety disorders,Acute alcohol withdrawal,Preoperative anxiety,Irritable bowel syndrome (off-label),Panic disorder (off-label)
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Primarily hepatic via CYP3A4; major metabolites are alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive).
Chlordiazepoxide is metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. Its active metabolites include desmethylchlordiazepoxide, demoxepam, and nordazepam.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
80% (primarily to albumin, minor to α1-acid glycoprotein)
90-98% bound to albumin and alpha-1-acid glycoprotein.
0.8 L/kg (range 0.6-1.2 L/kg); clinical meaning: moderate tissue distribution, reflects lipophilicity; higher Vd in obesity
0.5-0.8 L/kg; high Vd indicates extensive tissue distribution, with accumulation in adipose and brain tissue.
Oral: 90% (immediate-release); extended-release: approximately 90% relative to immediate-release; sublingual: approximately 75-80% of oral
Oral: 90-100% (well absorbed); IM: 80-100% (but variable due to precipitation at injection site); IV: 100%.
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 50% or consider alternative.
GFR 10-50 m L/min: administer 50-100% of usual dose; GFR <10 m L/min: administer 25-50% of usual dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Not FDA-approved for <18 years; limited data: 0.125 mg/kg/dose orally 3 times daily (max 0.02 mg/kg/dose) for panic disorder in adolescents.
Children 6-12 years: 5 mg orally 2-4 times daily, max 30 mg/day. Not recommended under 6 years.
Start with 0.25 mg orally 2-3 times daily; increase slowly due to increased sensitivity and risk of falls; maximum 2 mg/day.
Initial: 5 mg orally 1-2 times daily, increase cautiously; reduce total daily dose by 50% compared to younger adults.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; respiratory depression; worsening of depression or suicidal ideation; use in patients with acute narrow-angle glaucoma; impaired motor and cognitive performance; risk of severe allergic reactions.
Risk of dependence and withdrawal reactions,Potential for abuse and addiction,Respiratory depression, especially with concomitant CNS depressants,Central nervous system depressant effects, caution with impaired hepatic or renal function,Paradoxical reactions (e.g., agitation, aggression) in psychiatric patients,Suicidal ideation and behavior,Use in pregnancy: risk of neonatal sedation and withdrawal,Elderly patients: increased sensitivity and risk of falls
Concurrent use with ketoconazole or itraconazole; hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; severe hepatic impairment; pregnancy (especially first trimester) and breastfeeding.
Hypersensitivity to chlordiazepoxide or any benzodiazepine,Severe respiratory insufficiency,Sleep apnea syndrome,Severe hepatic impairment,Myasthenia gravis,Acute narrow-angle glaucoma,Concomitant use with ketoconazole, itraconazole, or other strong CYP3A4 inhibitors
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing alprazolam levels and risk of toxicity. Avoid alcohol. No other significant food interactions.
Avoid alcohol. No specific food interactions; take with or without food. Limit caffeine if it worsens symptoms.
First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties) with chronic high-dose use. Late third trimester: Risk of neonatal withdrawal syndrome.
First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless benefit justifies risk.
Excreted into breast milk; M/P ratio approximately 0.3-0.5. Relative infant dose ~2-3% of maternal weight-adjusted dose. Clinical significance: low but may cause sedation, poor feeding, or withdrawal in neonates. Use caution, monitor infant for lethargy and weight gain.
Excreted in breast milk; M/P ratio 0.25-0.5. Potential for infant sedation, poor feeding. Avoid breastfeeding or use alternative therapy.
Increased clearance and volume of distribution in pregnancy may require dose up-titration. Monitor clinical response; consider increasing dose by 20-50% in second and third trimesters. Avoid abrupt discontinuation; taper if needed. Use lowest effective dose for shortest duration.
Pregnancy may reduce plasma concentrations due to increased volume of distribution and enhanced clearance. Dose increases may be required, but avoid in pregnancy; if necessary, use lowest effective dose and limit duration.
Alprazolam is a short-acting benzodiazepine with a rapid onset. Due to its high potency and short half-life, it carries a high risk of dependence and withdrawal. Avoid in patients with narrow-angle glaucoma, severe respiratory insufficiency, or myasthenia gravis. Use with caution in patients with history of substance abuse. Taper gradually to prevent rebound anxiety and seizures. Onset of action is 15-30 min orally; peak effect at 1-2 hours.
CHLORDIAZACHEL is a combination of chlordiazepoxide (benzodiazepine) and clidinium (anticholinergic). Used for peptic ulcer and irritable bowel syndrome. Monitor for CNS depression and anticholinergic effects (dry mouth, blurred vision, constipation). Avoid in glaucoma, urinary retention, and myasthenia gravis. Discontinue gradually to prevent withdrawal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants as they can cause severe sedation and respiratory depression.,Do not drive or operate heavy machinery until you know how alprazolam affects you; it may cause drowsiness or dizziness.,Do not stop abruptly; withdrawal symptoms can include anxiety, insomnia, seizures, and life-threatening reactions.,Store at room temperature away from moisture and heat. Keep out of reach of children.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any worsening of depression or suicidal thoughts immediately.
Take exactly as prescribed; do not increase dose or duration.,Avoid alcohol and other CNS depressants.,May cause drowsiness; do not drive or operate machinery until effects are known.,Report bothersome side effects like constipation, dry mouth, or blurred vision.,Do not stop suddenly; taper under medical supervision.,Inform all healthcare providers you are taking this medication.
"Alprazolam, a benzodiazepine, potentiates the central nervous system (CNS) depressant effects of tetracaine, an ester-type local anesthetic. This additive or synergistic interaction can lead to excessive sedation, respiratory depression, and hypotension, particularly in elderly or debilitated patients. Concurrent use may also increase the risk of seizures due to tetracaine's proconvulsant activity at high doses, which is compounded by alprazolam's withdrawal-associated seizure risk."
"Co-administration of alprazolam, a benzodiazepine, with indinavir, a potent CYP3A4 inhibitor, significantly increases alprazolam's serum concentration and half-life via reduced hepatic metabolism, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Conversely, indinavir levels may be modestly increased due to competition for metabolism. This interaction poses a risk of severe central nervous system depression and should be avoided if possible."
"Concurrent use of alprazolam, a benzodiazepine with central nervous system depressant effects, and proparacaine, a topical ophthalmic anesthetic that can be systemically absorbed, may lead to additive CNS depression. This interaction can manifest as increased sedation, dizziness, confusion, or respiratory depression, especially in patients with compromised respiratory function or those receiving high doses of either agent. Clinicians should exercise caution when combining these drugs due to the potential for enhanced adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPRAZOLAM vs CHLORDIAZACHEL, answered by our medical review team.
ALPRAZOLAM is a Benzodiazepine that works by Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.. CHLORDIAZACHEL is a Benzodiazepine that works by Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPRAZOLAM and CHLORDIAZACHEL depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPRAZOLAM is: 0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.. The standard adult dose of CHLORDIAZACHEL is: Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPRAZOLAM and CHLORDIAZACHEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPRAZOLAM is classified as Category D/X. First trimester: Associated with increased risk of cleft lip/palate (OR 2.0); avoid if possible. Second/third trimester: Risk of benzodiazepine withdrawal or floppy infant syndrome. CHLORDIAZACHEL is classified as Category C. First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.